MYCHEL

Post-LOE

chloramphenicol

Pfizer

ANDAORALCAPSULE

Approved

Jun 1967

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

MYCHEL (chloramphenicol) by Pfizer is clinical pharmacology chloramphenicol is a broad-spectrum antibiotic originally isolated from streptomyces venezuelae . Approved for surface ocular infections involving the conjunctiva and/or cornea caused by chloramphenicol-susceptible organisms. First approved in 1967.

Drug data last refreshed 18h ago

Mechanism of Action

Clinical Pharmacology Chloramphenicol is a broad-spectrum antibiotic originally isolated from Streptomyces venezuelae . It is primarily bacteriostatic and acts by inhibition of protein synthesis by interfering with the transfer of activated amino acids from soluble RNA to ribosomes. It has been…

Indications (1)

surface ocular infections involving the conjunctiva and/or cornea caused by chloramphenicol-susceptible organisms

Worked on MYCHEL at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.